NACDS Marketplace In Brief: Private label ketoprofen
This article was originally published in The Tan Sheet
Executive Summary
Private label ketoprofen: Granutec reports that bioequivalence studies are under way for private label version of Whitehall-Robins' Orudis KT and Bayer's Actron analgesic brands. Ketoprofen's marketing exclusivity expires in December 1998. Granutec points to lackluster sales of the branded product, however, as a possible disincentive to pursue final approval. Sales of private label OTC naproxen sodium have exceeded the Wilson, N.C.-based company's forecasts...